Clarivate and CLEO diagnostics are making early detection of ovarian cancer a reality

An Australian company appears to be well on its way to achieving a significant medical breakthrough that promises to improve health outcomes for women around the world.

Cleo Diagnostics is in the process of finalizing the development of a simple yet accurate blood test that provides an early diagnosis for ovarian cancer, one of the most lethal female cancers. The company has IP protection in place for this diagnostics tool in the United States and Australia, with patents pending in other countries. Today, after 13-plus years of lab research and academic study, Cleo says the new diagnostics tool is poised for commercial success pending further testing and regulatory approval. However, according to CEO Richard Allman, Cleo wouldn't be nearly as close to getting its test into the hands of healthcare providers without leading solutions provided by Clarivate™, their longtime business partner.
Ovarian cancer is one of the deadliest of female cancers. Approximately half of all patients who are diagnosed will pass away within about five years of their diagnosis. The treatment is particularly complex because of the stage at which the cancer is diagnosed.

"We know that if these cancers can be detected at an early stage before they have grown and spread, survival is about 90 percent," said Andrew Stephens, Chief Scientific Officer and Executive Director at Cleo, an ASX-listed company. "However, because there are no symptoms and because there are no adequate diagnostics or screening modalities for ovarian cancer, almost all cases go undetected until they’re at a late stage when the cancer has spread quite extensively."

Currently, a diagnosis of ovarian cancer cannot be made until surgery is completed and the mass is examined by a pathologist, Stephens said. The benign, non-malignant disease is about 10 times more common than cancers, he said, which means many women who are referred to specialist surgeon don’t really need to go. "Conversely, many who may actually have cancer don’t end up with the right kind of surgeon."

To strategically position the blood test for success and drive adoption in a highly competitive market, Cleo relied on Clarivate insights and analysis, backed by comprehensive market research, Allman says. In recent years, Cleo has collaborated with Clarivate on a wide range of products and services, including Cortellis Drug Discovery Intelligence™ to identify crucial biomarker patterns critical for diagnostic accuracy, and Derwent™ patent intelligence software for intellectual property (IP) protection and regulatory advice.

"From Clarivate we can access market research, especially in those difficult-to-access areas like evaluating pathology data from other pathology companies," Allman says. "We’re also getting data and insights on IP and patent searches, meaning, competitor analysis, including searches for clinical trials that we may piggyback on to acquire clinical data.

"Essentially, the research solutions from Clarivate encompass all aspects of data and analytics that give us a commercial advantage," Allman says. "This is a big help as we aim to grow the business from zero to a global diagnostics brand."

Richard Allman, CEO at Cleo

"This is a big help as we aim to grow the business from zero to a global diagnostics brand."

"10X more people have non-malignant disease than cancers"
The promise of Cleo’s blood test

90% approximate survival rate if these cancers can be detected at an early stage.

Cleo is developing a series of tests aimed at improving clinical workflows, improving diagnoses and ultimately improving screening programs for women’s general health. The technology itself is a simple blood test that measures a series of biomarkers in a patient’s blood sample.

In its initial form, the test is used to assist in determining whether a suspicious mass might be cancerous or non-cancerous. This helps the physician send the patient to the right place for surgery. Ultimately, the test is used to guide decisions and improve outcomes across the board for all patients.

Longer-term, Cleo is looking to roll out additional testing to help patients who already have cancers and to develop a population-based screening program that will detect ovarian cancers at an early stage for all women.
Clarivate solutions for life sciences and healthcare

Clarivate connects data and solutions across the entire healthcare system, keeping the patient journey at the heart of everything the customer does. In its years-long consultancy with Cleo towards the goal of making strides in the early diagnosis of ovarian cancer.

Clarivate has provided numerous data-driven solutions, including:

- **Data expertise**
  Clarivate data analysts unravelled complex datasets to identify crucial biomarker patterns, enhancing diagnostic accuracy.

- **IP protection**
  The intellectual property strategy deployed by Clarivate safeguarded Cleo’s innovations, ensuring a competitive edge.

- **Regulatory mastery**
  Regulatory insights from Clarivate ensured that the Cleo blood test met evolving standards, expediting approval and commercialization.

- **Market precision**
  Market research conducted by Clarivate refined Cleo’s positioning strategy, driving adoption through tailored messaging.

Improving women's screening through the development of a simple test measuring a patient's blood for biomarkers.
About Clarivate

Clarivate is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

For more information about Clarivate, go to clarivate.com/life-sciences

For more information about Cleo, go to cleodx.com

Contact our experts today:

clarivate.com

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.